Basilea Pharmaceutica

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company headquartered in Allschwil, Switzerland, focused on the discovery, development, and commercialization of innovative medicines to treat severe bacterial and fungal infections. The company was founded in 2000 as a spin-off from Roche and has since established itself as a specialist in anti-infectives. Basilea's business model relies on a combination of internal R&D and strategic licensing partnerships to commercialize its products globally. Its portfolio includes two key marketed hospital brands, Cresemba (isavuconazole) for invasive fungal infections and Zevtera (ceftobiprole) for severe bacterial infections, alongside a pipeline of clinical and preclinical anti-infective assets.